Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

• ClinicalTrials.gov Identifier: NCT00379912
• Recruitment Status: Terminated
• First Posted: September 25, 2006
• Results First Posted: May 31, 2017
• Last Update Posted: February 14, 2018
• Sponsor: Larry Cripe, MD
• Collaborators: Celgene Corporation; Ortho Biotech Clinical Affairs, L.L.C.; Walther Cancer Institute
• Information provided by (Responsible Party): Larry Cripe, MD, Hoosier Cancer Research Network

Study Description

Brief Summary:

This trial is designed to explore a modified dose and schedule of azacitidine in order to more effectively address the needs of patients with low-risk myelodysplastic syndromes (MDS), i.e., to alter the natural history of the disease without excessive toxicity or burden. The administration of erythropoietin is designed to influence the differentiation of primitive hematopoietic cells in which azacitidine has reversed the abnormal phenotype to red blood cells for patients in whom inadequate production of red blood cells is the major clinical issue.

Condition or disease	Intervention/treatment	Phase
Myelodysplastic Syndromes	Drug: Azacitidine; Drug: Erythropoietin; Drug: Azacitidine (Monotherapy)	Phase 2

Detailed Description:

OUTLINE: This is an open label, multi-center, randomized study.

Eligible patients will be randomized to one of two treatment arms:

Arm A (Azacitidine + Erythropoietin)

• Azacitidine Treatment 50 mg/m2 subcutaneously every other day (three times a week) for two consecutive weeks every four weeks. A cycle of therapy is defined as two consecutive weeks of subcutaneous azacitidine administered every other day three times a week (e.g. Monday - Wednesday - Friday) and the time to resolution of any treatment associated toxicity.
• Erythropoietin Treatment Patients who are randomized to Arm A will receive a dose of 60,000IU as a single subcutaneous injection weekly without interruption while enrolled on protocol therapy. The dose should be administered to coincide with the first day of each cycle.
• Protocol therapy may be administered for up to six cycles of therapy.

Arm B (Azacitidine Alone)

• Azacitidine Treatment 50 mg/m2 subcutaneously every other day (three times a week) for two consecutive weeks every four weeks. A cycle of therapy is defined as two consecutive weeks of subcutaneous azacitidine administered every other day three times a week (e.g. Monday - Wednesday - Friday) and the time to resolution of any treatment associated toxicity.
• Protocol therapy may be administered for up to six cycles of therapy.

ECOG performance status 0 to 2

Hematopoietic:

To be eligible for randomization, subjects must have documentation of at least 1 of the following:

• A transfusion dependent anemia (defined by a history of two or more episodes of transfusion within a period of 8 weeks).
• An untransfused hemoglobin < 10 gm/dl measured on at least two occasions more than 7 days apart in the month prior to randomization.

Patients must also meet 1 of the following criteria:

• Has not received prior erythropoietin and has a serum erythropoietin level > 200 IU/L within 14 days of randomization.
• Has received prior erythropoietin without clinical benefit in the judgment of the treating physician.
• Adequate iron status defined as serum ferritin > 20 ng/ml and transferrin saturation of > 30% within 90 days prior to randomization.
• Symptoms attributed to the anemia with hemoglobin < 11 g/dL.
• Folate and Vitamin B12 levels within normal limits within 90 days prior to randomization.

Hepatic:

• SGOT (ALT) level < 2 x ULN within 14 days prior to randomization.
• SGPT (AST) level < 2 x ULN within 14 days prior to randomization.
• Serum total bilirubin level < 2 x ULN within 14 days prior to randomization.

Renal:

• Serum creatine < 1.5 x the upper limit of normal (ULN) within 14 days prior to randomization.

Cardiovascular:

• No uncontrolled hypertension (defined as a systolic pressure > 160 mmHg and/or a diastolic pressure > 110 mmHg).
• No history of (within 12 months) deep venous thrombosis (DVT), pulmonary embolism (PE), or other venous thrombosis. Prior superficial thrombophlebitis is not an exclusion criterion.
• No history of (within 6 months) cerebrovascular accident ([CVA] includes ischemic, embolic, and hemorrhagic), transient ischemic attack (TIA), myocardial ischemia (includes Unstable Angina, Q wave Myocardial Infarction [QwMI], and non-Q wave Myocardial Infarction [NQMI]), or other arterial thrombosis.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 15 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Randomized Trial With A Modified Dose & Schedule of Subcutaneously Administered Azacitidine & Erythropoietin v Azacitidine Alone in Patients With Low-Risk Myelodysplastic Syndromes (Less Than 11% Marrow & Peripheral Blood Blasts)
• Study Start Date: September 2006
• Actual Primary Completion Date: December 2008
• Actual Study Completion Date: December 2008

Arms and Interventions

Arm	Intervention/treatment
Experimental: Investigational Arm A; Azacitidine + Erythropoietin	Drug: Azacitidine; Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.; Other Name: Vidaza; Drug: Erythropoietin; Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy; Other Name: EPO
Experimental: Investigational Arm B; Azacitidine	Drug: Azacitidine (Monotherapy); Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.; Other Name: Vidaza

Outcome Measures

Primary Outcome Measures :

1. Overall Response After Cycle 3 [ Time Frame: 3 months ]

   Overall response for participants who have completed at least three cycles of protocol-specified therapy according to the International Working Group to Standardize Response Criteria for Myelodysplastic Syndromes criteria for Erythroid Response (HI-E) Major response: For patients with pretreatment hemoglobin less than 11 g/dL, greater than 2 g/dL increase in hemoglobin; for RBC transfusion-dependent patients, transfusion independence.

   Minor response: For patients with pretreatment hemoglobin less than 11 g/dL, 1 to 2 g/dL increase in hemoglobin; for RBC transfusion-dependent patients, 50% decrease in transfusion requirements.

2. Overall Response Rate After Six Cycles [ Time Frame: 6 months ]

   Overall response rate for participants who have completed at least six cycles of protocol-specified therapy according to the International Working Group to Standardize Response Criteria for Myelodysplastic Syndromes criteria for Erythroid Response (HI-E) Major response: For patients with pretreatment hemoglobin less than 11 g/dL, greater than 2 g/dL increase in hemoglobin; for RBC transfusion-dependent patients, transfusion independence.

   Minor response: For patients with pretreatment hemoglobin less than 11 g/dL, 1 to 2 g/dL increase in hemoglobin; for RBC transfusion-dependent patients, 50% decrease in transfusion requirements.

Secondary Outcome Measures :

1. Safety Profile of the Modified Dose/Schedule of Azacitidine and Erythropoietin or a Modified Dose of Azacitidine Alone [ Time Frame: 24 months ]
   Full adverse event information is submitted in the record below. A summary of the Significant Toxicities Rate (clinically significant myelosuppression (CTCAE Grade 3 or 4 neutropenia or thrombocytopenia)) over all patients receiving at least 1 dose of study medication at the time of interim analysis is reported in this outcome measure.
2. Duration of Significant Responses [ Time Frame: 24 months ]
   Data for this outcome measure was not collected or analyzed due to the termination of the study.
3. Quality of Life [ Time Frame: 24 months ]
   Data for this outcome measure was not collected or analyzed due to the termination of the study
4. Analysis of CD34, CD71, CD36 Cells in Aspirated Bone Marrow for Both Responders and Non-responders at Baseline and After Three and Six Cycles [ Time Frame: 6 months ]
5. Percent Apoptosis in 34+36+71+ Cells at Baseline, Three Cycles and Six Cycles [ Time Frame: Six months ]
6. BclXL Expression [ Time Frame: Six months ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• A bone marrow (BM) aspirate and biopsy that demonstrates MDS with less than 11% blasts.
• Conventional metaphase cytogenetics done within 90 days prior to registration for screening.
• Central pathology review, correlative submission and confirmation of diagnosis is required prior to initiation of therapy (see Study Procedure Manual for details of submission). The FAB and WHO classification of MDS and the IPSS score will be determined at time of central pathology review.
• Correlative marrow aspirate obtained.

To be eligible for randomization, subjects must have documentation of at least 1 of the following:

• A transfusion dependent anemia (defined by a history of two or more episodes of transfusion within a period of 8 weeks).
• An untransfused hemoglobin < 10 gm/dl measured on at least two occasions more than 7 days apart in the month prior to randomization.

Patients must also meet 1 of the following criteria:

• Has not received prior erythropoietin and has a serum erythropoietin level > 200 IU/L within 14 days of randomization.
• Has received prior erythropoietin without clinical benefit in the judgment of the treating physician.
• Adequate iron status defined as serum ferritin > 20 ng/ml and transferrin saturation of > 30% within 90 days prior to randomization.
• Symptoms attributed to the anemia with hemoglobin < 11 g/dL.
• Folate and Vitamin B12 levels within normal limits within 90 days prior to randomization.
• Life expectancy > 6 months as judged by the treating investigator.

Exclusion Criteria:

• No known history of intolerance to erythropoietic agents.
• No prior intensive cytotoxic chemotherapy for a myeloid malignancy including MDS.
• Patients with a history of a non-myeloid malignancy with secondary MDS are eligible for study enrollment provided, in the opinion of the treating investigator and the study chair, the anticipated behavior of the non-myeloid malignancy will not interfere with study participation and evaluation of outcome.
• No known or suspected hypersensitivity to azacitidine or mannitol.
• No hepatic tumors.
• No uncontrolled hypertension (defined as a systolic pressure > 160 mmHg and/or a diastolic pressure > 110 mmHg).
• No known hypersensitivity to mammalian cell-derived products or human albumin.
• No history of (within 12 months) deep venous thrombosis (DVT), pulmonary embolism (PE), or other venous thrombosis. Prior superficial thrombophlebitis is not an exclusion criterion.
• No history of (within 6 months) cerebrovascular accident ([CVA] includes ischemic, embolic and hemorrhagic), transient ischemic attack (TIA), myocardial ischemia (includes Unstable Angina, Q wave Myocardial Infarction [QwMI] and non-Q wave Myocardial Infarction [NQMI], or other arterial thrombosis.
• Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) while on treatment and for a 4-week period thereafter.
• Females with childbearing potential must have a negative pregnancy test within 7 days prior to being randomized. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.

Contacts and Locations

Locations

United States, Illinois

Medical & Surgical Specialists, LLC

Galesburg, Illinois, United States, 61401

United States, Indiana

Indiana University Cancer Center

Indianapolis, Indiana, United States, 46202

Quality Cancer Center (MCGOP)

Indianapolis, Indiana, United States, 46202

Arnett Cancer Care

Lafayette, Indiana, United States, 47904

Horizon Oncology Center

Lafayette, Indiana, United States, 47905

Medical Consultants, P.C.

Muncie, Indiana, United States, 47303

Northern Indiana Cancer Research Consortium

South Bend, Indiana, United States, 46601

United States, Michigan

Center for Hematology-Oncology of S Michigan

Jackson, Michigan, United States, 49201

United States, Nebraska

Methodist Cancer Center

Omaha, Nebraska, United States, 68114

Sponsors and Collaborators

Larry Cripe, MD

Celgene Corporation

Ortho Biotech Clinical Affairs, L.L.C.

Walther Cancer Institute

Investigators

• Study Chair: Larry Cripe, M.D.; Hoosier Oncology Group, LLC

More Information

Additional Information:

Hoosier Oncology Group Home Page 

Publications of Results:

Sayar H, Chan RJ, Orschell CM, Chan EM, Yu Z, Hood D, Plett A, Yang Z, Hui CL, Nabinger SC, Kohlbacher KJ, West ES, Walter A, Sampson C, Wu J, Cripe LD. Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group. Leuk Res. 2011 Aug;35(8):1108-10. doi: 10.1016/j.leukres.2011.02.025. Epub 2011 Mar 21.

• Responsible Party: Larry Cripe, MD, Sponsor-Investigator, Hoosier Cancer Research Network
• ClinicalTrials.gov Identifier: NCT00379912
• Other Study ID Numbers: HOG MDS04-85
• First Posted: September 25, 2006
• Results First Posted: May 31, 2017
• Last Update Posted: February 14, 2018
• Last Verified: January 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Preleukemia; Myelodysplastic Syndromes; Syndrome; Disease; Pathologic Processes; Bone Marrow Diseases; Hematologic Diseases; Precancerous Conditions; Neoplasms; Azacitidine; Epoetin Alfa; Antimetabolites, Antineoplastic; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Enzyme Inhibitors; Hematinics